Tenderwize
Retour à la recherche

Open-house rebate agreement for Alfacalcidol

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 406 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Alfacalcidol, ATC A11CC03

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

The notice requires either handwritten original documents or documents signed with a qualified electronic signature; or...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Nov 30, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Alfacalcidol (ATC A11CC03).
  • Supply of only authorised and marketable medicines in Germany.
Afficher le résumé complet

This is an open-house supply arrangement for pharmaceutical products with AOK Rheinland-Pfalz/Saarland for the active substance Alfacalcidol (ATC A11CC03). It is non-exclusive, open to pharmaceutical companies only, with uniform terms and no individual negotiation. The contract period runs from 01.02.2026 to 31.01.2028, with monthly entry possible during the term. No contract value is stated. Submission is not electronic-only: handwritten originals or electronically signed documents by email are allowed, but the notice says electronic submission is otherwise not allowed. Procurement documents appear available via DTVP, but no procurement document text beyond the TED XML notice was provided for analysis.

Risques

The notice requires either handwritten original documents or documents signed with a qualified electronic signature; or...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Medicines must be authorised and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce database extract must be provided.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Alfacalcidol

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Alfacalcidol (ATC A11CC03). The scope excludes medicines on the BfArM list under Section 35(5a) SGB V (children's medicines). Contract terms are uniform for all participants; no individual negotiations. Contract start is earliest 01.02.2026 and contracts may be entered monthly during the 24-month period. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 30, 2027

Détails de la procédure

Date de publication
09 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
817817-2025

Documents (1)

Appels d'offres similaires